期刊文献+

艾司西酞普兰联合奥氮平治疗老年精神分裂症伴抑郁临床疗效和安全性 被引量:20

Clinical Efficacy and Safety of Escitalopram Citalopram Combined with Olanzapine for the Treatment of Senile Schizophrenia with Depression
下载PDF
导出
摘要 【目的】探讨艾司西酞普兰联合奥氮平治疗老年精神分裂症伴抑郁的临床疗效和安全性。【方法】将80例老年精神分裂症伴抑郁患者随机分为对照组和观察组各40例,观察组给予艾司西酞普兰合用奥氮平治疗,对照组给予奥氮平治疗,疗程12周。于治疗前和治疗后4、8、12周分别使用汉密尔顿抑郁量表(HAMD)和不良反应量表(TESS)进行测评。【结果】治疗前两组 HAMD 评分差异无统计学意义( P >0.05)。治疗4、8、12周后,观察组和对照组的 HAMD评分均低于治疗前( P <0.05);观察组4、8、12周HAMD评分均低于对照组( P <0.05);观察组有效率(85.0%)显著高于对照组(60.0%)( P <0.05);两组间不良反应发生率差异无统计学意义( P >0.05)。【结论】艾司西酞普兰合用奥氮平治疗老年精神分裂症伴抑郁疗效较好,安全性高。 [Objective] To explore clinical efficacy and safety of escitalopram citalopram combined with olanzapine for the treatment of senile schizophrenia with depression .[Methods] Eighty elderly patients with schizophrenia and depression were randomly divided into control group and observation group .The observation group( n=40) was given escitalopram citalopram combined with olanzapine treatment ,while the control group ( n = 40) was given olanzapine treatment .The treatment lasted for 12 weeks .Hamilton depression scale (HAMD) and treatment emergent symptom scale(TESS) was used to assess before and 4 ,8 and 12 weeks af-ter treatment .[Results]There was no significant difference in HAMD scores between two groups before treat-ment( P 〉0 .05) .HAMD scores of observation group and control group 4 ,8 and 12 weeks after treatment were lower than those before treatment ( P 〈 0 .05) .HAMD scores of observation group were lower than those of control group at 4 ,8 and 12 weeks(P〈0 .05) .The effective rate of observation group was higher than that of control group(85 .0% vs .60 .0% ,P〈0 .05) .There was no significant difference in the incidence of adverse reactions between two groups ( P 〉 0 .05) .[Conclusion]Escitalopram citalopram combined with olanzapine for the treatment of senile schizophrenia with depression has good efficacy and high safety .
出处 《医学临床研究》 CAS 2014年第3期495-497,共3页 Journal of Clinical Research
关键词 精神分裂症 并发症 抑郁症 药物疗法 老年人 Schizophrenia/CO Depressive Disorder/DT Aged
  • 相关文献

参考文献9

  • 1Boyer L, Baumstarck K, Boucekine M, et al . Measuring quality of life in patients with schizophrenia: an overview[J]. Expert Rev Pharmacoecon Outcomes Res , 2013,13 (3) = 343-349.
  • 2孟广彦,赵长英,陈贞娥,孟淑贤,侯庆香,郝宝利,刘俊,王守丽,宁静,吕静,史守月,窦秀云.济南市18岁及以上人群精神障碍流行病学抽样调查[J].精神医学杂志,2011,24(3):176-179. 被引量:9
  • 3朱金玲,蒋良函,卫昭华,陆光华.国内住院慢性精神分裂症患者社会功能康复现状研究[J].齐鲁护理杂志,2013,19(1):46-48. 被引量:13
  • 4谢侃侃,张国富,李艳,罗小年.北京城区精神分裂症家属经济负担与生存质量[J].临床精神医学杂志,2011,21(2):84-86. 被引量:16
  • 5Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a sys- tematic review and meta-analysis[J].Lancet , 2012, 379(9831) :2063-2071.
  • 6Hartling L, Abou-Setta AM, Dursun S, et al . Antipsychotics in adults with schizophrenia; comparative effectiveness of first- generation versus second-generation medications: a systematic review and meta-analysis[J]. Ann Intern Med , 2012,157 (7) 498-511.
  • 7中华医学会精神科分会.中国精神障碍分类与诊断标准[M].第3版.济南:山东科学技术出版社,2011:87-90.
  • 8齐小强.精神分裂症抑郁[J].国外医学(精神病学分册),2002,29(1):15-17. 被引量:24
  • 9Holthausen EA, Wiersma D, Knegtering RH, et al . Psychopa- thology and cognition in schizophrenia spectrum disorders:the role of depressive symptoms [J]. Schizophr Res , 1999,39 (1) 65-71.

二级参考文献34

共引文献61

同被引文献140

  • 1陈华德,殷光磊,蒋飚,何伟良.用fMRI技术探讨针刺百会穴对脑功能的影响[J].浙江中医药大学学报,2006,30(6):656-659. 被引量:49
  • 2中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108-1150.
  • 3中华医学会精神科分会.中国精神疾病分类方案与诊断标准[M].3版.济南:山东科学技术出版社,2001.
  • 4Meesters PD,de Haan L,Comijs HC,et al.Schizophrenia spectrum disorders in later life:prevalence and distribution of age at onset and sex in a Dutch catchment area[J].Am J Ger Psychiatry,2012,20:18-28.
  • 5Riedel M,Mayr A,Seemüller F,et al.Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients:comparing treatment with risperidone and haloperidol[J].World J Biol Psychiatry,2012,13:30-38.
  • 6Khan A,Faucett J,Morrison S,et al.Comparative mortality risk in adult patients with Schizophrenia,depression,bipolar disorder,anxiety disorders,and attention-deficit/hyperactivity disorder participating in Psychopharmacology Clinical Trials[J].JAMA psychiatry,2013,70:1091-1099.
  • 7Araragi N,Lesch KP.Serotonin(5-HT)in the regulation of depression-related emotionality:insight from 5-HT transporter and tryptophan hydroxylase-2 knockout mouse models[J].Curr Drug Targets,2013,14:549-570.
  • 8Pujia F,Serrao M,Brienza M,et al.Effects of a selective serotonin reuptake inhibitor escitalopram on the cutaneous silent period:A randomized controlled study in healthy volunteers[J].Neurosci Lett,2014,566:17-20.
  • 9Stryjer R,Dambinsky Y,Timinsky I,et al.Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder:an open-label,prospective study[J].Int Clin Psychopharmacol,2013,28:96-98.
  • 10Steel C, van der Gaag M, Korrelboom K, et al. A randomised controlled trial of posi- tive memory training for the treatment of depression within schizophrenia[J].BMC Psychiatry,2015,15(1):85.

引证文献20

二级引证文献140

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部